Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,764 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Participant Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

NCT05511558
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-Fosgonimeton
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jun 10, 2026, 10:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Timing of Voluntary Movement in Patients With Schizophrenia

NCT00080548
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations

NCT00665743
View directory record Official record
Conditions
Arthritis
Interventions
PN400, naproxen
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2008 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Retapamulin Microdialysis Feasibility Study

NCT01812382
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retapamulin Microdialysis
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

NCT00717262
View directory record Official record
Conditions
Healthy
Interventions
HQK-1001, placebo
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 15, 2009 · Synced Jun 10, 2026, 10:06 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

NCT00780325
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CG100649 (2 mg), Celecoxib, Placebo capsules, Naproxen, Acetazolamide, CG100649 (8 mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dinner Time 2: Effect of Delayed Eating or Sleeping on Metabolism

NCT04671797
View directory record Official record
Conditions
Healthy
Interventions
Early dinner, Late Dinner, Late Dinner + Late Sleep
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 30 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg

NCT00648388
View directory record Official record
Conditions
Healthy
Interventions
Cilostazol Tablets 100 mg, Pletal® Tablets 100 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jun 10, 2026, 10:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Educational Impact of the NLM/National Area Health Education Center Organization (NAO) Project-SHARE Based Teen Health Information Literacy Curriculum

NCT02769988
View directory record Official record
Conditions
Healthy Volunteers Only
Interventions
Not listed
Lead sponsor
National Library of Medicine (NLM)
NIH
Eligibility
13 Years to 18 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
6
States / cities
Durango, Colorado • Greeley, Colorado • New London, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults

NCT03764488
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tofersen, 99mTc-MAG3-BIIB067
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

NCT01232413
View directory record Official record
Conditions
Healthy Subjects, Cardiac Repolarization
Interventions
Placebo, ASP1941, Moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals

NCT02536846
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine
Drug
Lead sponsor
Dost Ongur
Other
Eligibility
21 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Jun 10, 2026, 10:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

NCT02242968
View directory record Official record
Conditions
Vaccines, Antiviral Agents, Immunologic Factors, Physiological Effects of Drugs, Anti-Infective Agents
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jun 10, 2026, 10:06 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

NCT05799274
View directory record Official record
Conditions
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
RAD301 ([68Ga]-RAD301)
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Princeton, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

NCT04571424
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB133 (Dapirolizumab pegol), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Concussion Therapy Intervention Training in Healthy and Concussed Participants

NCT02872480
View directory record Official record
Conditions
Cerebral Concussion
Interventions
ACTIVE Training
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961308
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
11 Years to 14 Years
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
20
States / cities
Mobile, Alabama • San Diego, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

NCT05395117
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5462, Midazolam, Rosuvastatin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

NCT05226923
View directory record Official record
Conditions
Bacterial Infections
Interventions
KSP-1007, Placebo:0.9% sodium chloride, Meropenem
Drug · Other
Lead sponsor
Sumitovant Biopharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions

NCT00835588
View directory record Official record
Conditions
Healthy
Interventions
Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
2
States / cities
Saint Charles, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

NCT03363815
View directory record Official record
Conditions
Heathy Volunteer
Interventions
CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib
Drug · Dietary Supplement
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jun 10, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects

NCT00942240
View directory record Official record
Conditions
Healthy
Interventions
ACU-4429, matching placebo tablet
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Jun 10, 2026, 10:06 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

NCT00580190
View directory record Official record
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Jun 10, 2026, 10:06 AM EDT